FY2025 Earnings Forecast for Immunic Issued By William Blair

Immunic, Inc. (NASDAQ:IMUX) – Research analysts at William Blair issued their FY2025 EPS estimates for shares of Immunic in a research note issued on Monday, March 24th. William Blair analyst M. Minter expects that the company will post earnings per share of ($0.89) for the year. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share.

IMUX has been the topic of a number of other research reports. D. Boral Capital reissued a “buy” rating and set a $17.00 price objective on shares of Immunic in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Immunic in a research note on Friday, February 21st. Finally, StockNews.com cut Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, March 20th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Immunic has a consensus rating of “Buy” and an average target price of $12.67.

Immunic Stock Up 3.3 %

Shares of NASDAQ IMUX opened at $1.24 on Wednesday. The firm has a market cap of $111.70 million, a PE ratio of -1.01 and a beta of 1.89. The company’s fifty day simple moving average is $1.08 and its 200 day simple moving average is $1.21. Immunic has a 12-month low of $0.92 and a 12-month high of $2.11.

Institutional Investors Weigh In On Immunic

Several institutional investors have recently bought and sold shares of the stock. Invesco Ltd. purchased a new position in Immunic during the 4th quarter worth $37,000. Virtu Financial LLC bought a new position in shares of Immunic during the third quarter valued at about $50,000. HB Wealth Management LLC purchased a new position in Immunic during the fourth quarter worth about $81,000. Barclays PLC bought a new stake in Immunic in the 4th quarter worth about $84,000. Finally, Jane Street Group LLC increased its stake in Immunic by 121.4% in the 3rd quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the last quarter. Institutional investors own 51.82% of the company’s stock.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.